Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Inactive on SAM.gov — responses were due 5 Jan 2026 · Unrestricted (full and open) · Defense Health Agency (DHA), DoD · San Antonio, TX · NAICS 325412 · Solicitation HT9402-26-Q-9103
Following NAICS 325412? Get new solicitations in it by email as they post — no account needed.
SAM.gov marked this notice inactive — responses were due 05 January 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 325412 (Pharmaceutical Preparation Manufacturing) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
The Department of Defense (DoD) is required by law (10 U.S.C. 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2026 newly approved drugs will be reviewed: a. Hyrnuo - Lung Cancer - HER2+ b. Javadin - Antihypertensive Agents - N/A c. Komzifti - Leukemia and Lymphoma Agents - Acute Myelogenous Leukemia d. Lasix ONYU - Diuretics - N/A e. Redemplo - Antilipidemics-2 - N/A f. Starjemza - Targeted Immunomodulatory Biologics - Interleukin 23 The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9103. Pre-quotation teleconference is on December 17, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Version history
SAM.gov has posted 2 notices under solicitation HT9402-26-Q-9103, oldest first.
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
